Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis
ObjectiveEfgartigimod (EFG), a neonatal Fc receptor antagonist that facilitates the degradation of pathogenic immunoglobulin G, is approved for the treatment of generalized myasthenia gravis (MG). This study aims to evaluate the efficacy and safety of EFG in patients with very-late-onset myasthenia...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2025-04-01
|
| Seri Bilgileri: | Frontiers in Immunology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579859/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|